USD 0.35
(0.0%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 | -544.19 Thousand USD | -150.19% |
2023 | -217.51 Thousand USD | 55.19% |
2022 | 55.1 Thousand USD | -1821.43% |
2021 | 760.82 Thousand USD | 255.56% |
2020 | -17.12 Thousand USD | -387.01% |
2019 | -3693.00 USD | -100.62% |
2018 | 599.09 Thousand USD | 229.37% |
2017 | -444.69 Thousand USD | 34.6% |
2016 | -514.6 Thousand USD | 40.25% |
2015 | -993.31 Thousand USD | -52.12% |
2014 | -1.24 Million USD | -41.63% |
2013 | -295.61 Thousand USD | -160.43% |
2012 | -208.02 Thousand USD | -168.37% |
2011 | 310.59 Thousand USD | 0.95% |
2010 | 543.88 Thousand USD | -28.25% |
2009 | 426.45 Thousand USD | 651.28% |
2008 | 67.41 Thousand USD | -14.75% |
2007 | 78.24 Thousand USD | 153.86% |
2006 | -120.96 Thousand USD | 67.37% |
2005 | -384.52 Thousand USD | -279.58% |
2004 | 202.68 Thousand USD | -36.0% |
2003 | 207.85 Thousand USD | 311.87% |
2002 | -159.49 Thousand USD | 84.42% |
2001 | -998.43 Thousand USD | 48.19% |
2000 | -1.93 Million USD | 13.46% |
1999 | -2.23 Million USD | 34.21% |
1998 | -3.4 Million USD | -1.14% |
1997 | -3.34 Million USD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | -106 Thousand USD | -81.69% |
2024 Q3 | -168.82 Thousand USD | -636.41% |
2024 FY | - USD | -157.2% |
2024 Q4 | -381.14 Thousand USD | -86.52% |
2024 Q2 | 27.75 Thousand USD | 129.67% |
2023 Q3 | -211 Thousand USD | 16.87% |
2023 FY | - USD | 55.19% |
2023 Q4 | -57.13 Thousand USD | 72.92% |
2023 Q2 | -253.82 Thousand USD | -188.44% |
2023 Q1 | 287 Thousand USD | 925.0% |
2022 Q1 | 22 Thousand USD | -87.43% |
2022 FY | - USD | -1821.43% |
2022 Q4 | 28 Thousand USD | 64.71% |
2022 Q3 | 17 Thousand USD | 111.81% |
2022 Q2 | -144 Thousand USD | -754.55% |
2021 Q1 | -123 Thousand USD | -70.83% |
2021 FY | - USD | 255.56% |
2021 Q2 | -57 Thousand USD | 53.66% |
2021 Q4 | 175 Thousand USD | 414.71% |
2021 Q3 | 34 Thousand USD | 159.65% |
2020 FY | - USD | -387.01% |
2020 Q4 | -72 Thousand USD | -161.02% |
2020 Q3 | 118 Thousand USD | 63.89% |
2020 Q1 | -136 Thousand USD | 2.52% |
2020 Q2 | 72 Thousand USD | 152.94% |
2019 Q2 | 84 Thousand USD | -2.33% |
2019 FY | - USD | -100.62% |
2019 Q4 | -139.5 Thousand USD | -298.6% |
2019 Q3 | -35 Thousand USD | -141.67% |
2019 Q1 | 86 Thousand USD | 82.98% |
2018 FY | - USD | 229.37% |
2018 Q3 | 123 Thousand USD | -31.28% |
2018 Q4 | 47 Thousand USD | -61.79% |
2018 Q2 | 179 Thousand USD | -28.4% |
2018 Q1 | 250 Thousand USD | 681.4% |
2017 Q2 | -244 Thousand USD | -187.06% |
2017 Q4 | -43 Thousand USD | 83.33% |
2017 FY | - USD | 34.6% |
2017 Q1 | -85 Thousand USD | 68.16% |
2017 Q3 | -258 Thousand USD | -5.74% |
2016 Q2 | -122 Thousand USD | 29.48% |
2016 FY | - USD | 40.25% |
2016 Q4 | -267 Thousand USD | -82.88% |
2016 Q3 | -146 Thousand USD | -19.67% |
2016 Q1 | -173 Thousand USD | 44.55% |
2015 Q4 | -312 Thousand USD | 14.05% |
2015 FY | - USD | -52.12% |
2015 Q1 | -146 Thousand USD | 87.89% |
2015 Q2 | -364 Thousand USD | -149.32% |
2015 Q3 | -363 Thousand USD | 0.27% |
2014 Q1 | -164 Thousand USD | 23.72% |
2014 Q3 | 98 Thousand USD | 326.09% |
2014 Q2 | 23 Thousand USD | 114.02% |
2014 FY | - USD | -41.63% |
2014 Q4 | -1.2 Million USD | -1330.33% |
2013 Q3 | -83 Thousand USD | 68.44% |
2013 Q1 | 12 Thousand USD | -89.68% |
2013 Q2 | -263 Thousand USD | -2291.67% |
2013 FY | - USD | -160.43% |
2013 Q4 | -215 Thousand USD | -159.04% |
2012 Q1 | 55.13 Thousand USD | -49.63% |
2012 Q4 | 116.24 Thousand USD | 3182.89% |
2012 Q2 | -386.24 Thousand USD | -800.56% |
2012 Q3 | 3541.00 USD | 100.92% |
2012 FY | - USD | -168.37% |
2011 Q4 | 109.44 Thousand USD | -64.87% |
2011 Q1 | -46.11 Thousand USD | -26.49% |
2011 FY | - USD | 0.95% |
2011 Q3 | 311.52 Thousand USD | 572.37% |
2011 Q2 | -65.94 Thousand USD | -43.01% |
2010 FY | - USD | -28.25% |
2010 Q1 | 241.15 Thousand USD | 161.03% |
2010 Q2 | 124.82 Thousand USD | -48.24% |
2010 Q3 | 212.71 Thousand USD | 70.41% |
2010 Q4 | -36.45 Thousand USD | -117.14% |
2009 Q2 | 155.49 Thousand USD | 216.03% |
2009 Q4 | 92.38 Thousand USD | -70.44% |
2009 Q1 | -134.01 Thousand USD | -202.48% |
2009 FY | - USD | 651.28% |
2009 Q3 | 312.58 Thousand USD | 101.02% |
2008 Q1 | -242.99 Thousand USD | -98.97% |
2008 Q4 | 130.76 Thousand USD | 4.76% |
2008 Q3 | 124.82 Thousand USD | 182.57% |
2008 Q2 | 44.17 Thousand USD | 118.18% |
2008 FY | - USD | -14.75% |
2007 Q3 | -6426.00 USD | -113.43% |
2007 Q2 | 47.85 Thousand USD | -67.5% |
2007 FY | - USD | 153.86% |
2007 Q4 | -122.12 Thousand USD | -1800.54% |
2007 Q1 | 147.23 Thousand USD | 308.16% |
2006 Q1 | 76.61 Thousand USD | 307.38% |
2006 Q4 | 36.07 Thousand USD | 129.71% |
2006 Q3 | -121.41 Thousand USD | -5.65% |
2006 Q2 | -114.91 Thousand USD | -249.99% |
2006 FY | - USD | 67.37% |
2005 Q1 | -245.43 Thousand USD | -3042.91% |
2005 Q3 | -88.39 Thousand USD | -985.07% |
2005 Q2 | -8146.00 USD | 96.68% |
2005 FY | - USD | -279.58% |
2005 Q4 | -36.94 Thousand USD | 58.2% |
2004 Q4 | -7809.00 USD | -114.54% |
2004 FY | - USD | -36.0% |
2004 Q3 | 53.71 Thousand USD | -38.69% |
2004 Q2 | 87.61 Thousand USD | 13.09% |
2004 Q1 | 77.47 Thousand USD | -27.23% |
2003 Q3 | 147.82 Thousand USD | 65.22% |
2003 Q2 | 89.62 Thousand USD | 264.93% |
2003 FY | - USD | 311.87% |
2003 Q1 | -69.06 Thousand USD | -25.31% |
2003 Q4 | 107.81 Thousand USD | -40.94% |
2002 Q2 | 49.68 Thousand USD | 193.14% |
2002 Q1 | -55.63 Thousand USD | 77.29% |
2002 Q3 | -100.17 Thousand USD | -291.87% |
2002 Q4 | -53.37 Thousand USD | 46.69% |
2002 FY | - USD | 84.42% |
2001 FY | - USD | 48.19% |
2001 Q4 | -243.95 Thousand USD | -16.93% |
2001 Q3 | -186.74 Thousand USD | -1.05% |
2001 Q2 | -231.04 Thousand USD | 39.16% |
2001 Q1 | -354.3 Thousand USD | 43.55% |
2000 Q3 | -515.63 Thousand USD | 0.0% |
2000 Q4 | -603.72 Thousand USD | -16.6% |
2000 FY | - USD | 13.46% |
1999 FY | - USD | 34.21% |
1998 FY | - USD | -1.14% |
1997 FY | - USD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
American Medical Technologies Inc. | -963.95 Thousand USD | 43.546% |
Ansell Limited | 209.86 Million USD | 100.259% |
Ansell Limited | 206.3 Million USD | 100.264% |
BG Medicine, Inc. | - USD | Infinity% |
Biotage AB (publ) | 42.83 Million USD | 101.27% |
BioLife Sciences Inc. | - USD | Infinity% |
CB Scientific, Inc. | -1.62 Million USD | 66.51% |
Psykey, Inc. | -1.29 Million USD | 57.987% |
ConvaTec Group Plc | 455.5 Million USD | 100.119% |
ConvaTec Group Plc | 455.5 Million USD | 100.119% |
Golden Valley Development, Inc | -141.81 Thousand USD | -283.749% |
Hear AtLast Holdings, Inc. | -109.93 Thousand USD | -395.038% |
Innovative MedTech Inc. | -7.67 Million USD | 92.908% |
LifePoint, Inc. | -14.2 Million USD | 96.168% |
Medite Cancer Diagnostics, Inc. | -6.18 Million USD | 91.204% |
Paradigm Medical Industries, Inc. | -325 Thousand USD | -67.445% |
QuantRx Biomedical Corporation | - USD | Infinity% |
Remedent, Inc. | -215.23 Thousand USD | -152.839% |
Reflect Scientific, Inc. | -405.78 Thousand USD | -34.11% |
SmileDirectClub, Inc. | -186.13 Million USD | 99.708% |
Sector 10, Inc. | - USD | Infinity% |
Shandong Weigao Group Medical Polymer Company Limited | 447.82 Million USD | 100.122% |
SheerVision, Inc. | -110.53 Thousand USD | -392.346% |
United Health Products, Inc. | -2.5 Million USD | 78.251% |
Vasamed, Inc. | -4.57 Million USD | 88.104% |
Wearable Health Solutions, Inc. | -2.26 Million USD | 75.928% |
Yubo International Biotech Limited | -1.17 Million USD | 53.791% |